OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
42 hedge funds and large institutions have $13.1M invested in OncoMed Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 16 closing their positions.
22% less funds holding
Funds holding: 54 → 42 (-12)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
68% less capital invested
Capital invested by funds: $40.2M → $13.1M (-$27.2M)
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$2.86M |
| 2 |
Renaissance Technologies
New York
|
+$604K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$114K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$82.3K |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
+$81.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.36M |
| 2 |
NC
Nexthera Capital
New York
|
-$1.35M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$988K |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$839K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$465K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| – | -$36K | -17,025 | Closed |
|
52
Simplex Trading
Chicago,
Illinois
| – | -$5.92K | -3,933 | -100% |
|
|
MAM
53
Meeder Asset Management
Dublin,
Ohio
| – | -$7K | -3,084 | Closed |
|
|
LTFS
54
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$151 | +100 | New |
|
OMED Hedge Fund Activity: Q4 2018 in Review
42 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2018, worth a combined $13.1M — down 68% from $40.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of OMED and 4 opened new positions — a net loss of 12 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was Harbourvest Partners, opening a new position worth an estimated $2.86M. The largest seller was Perceptive Advisors, cutting an estimated $1.36M.
- 42 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2018, down from 54 in Q3 2018.
- Funds reported $13.1M of OncoMed Pharmaceuticals, Inc. stock for Q4 2018, down 68% quarter-over-quarter.
- 4 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2018 and 16 closed out, a net change of -12 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2018 was Harbourvest Partners, an estimated $2.86M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2018 was Perceptive Advisors, an estimated $1.36M sold.
Based on aggregated 13F filings for Q4 2018.